Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 5/20 | 0.47 |
| ▸ | CDK2 | P24941 | 5/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.43 |
| ▸ | EP300 | Q09472 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720830 | 0.89 | BTK (0.47) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL5720882 | 0.84 | AURKA (0.51) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL5720853 | 0.84 | L3MBTL1 (0.47) | CCNA2CDK2CCNA1AURKAMAPT | |
| SCHEMBL5720821 | 0.82 | CKS1B (0.42) | MAPK1LMNA | |
| SCHEMBL5720872 | 0.76 | GRM5 (0.46) | CCNA2CDK2CCNA1AURKANOTUM | |
| SCHEMBL2920173 | 0.76 | CCNA2 (0.39) | CCNA2CDK2CCNA1AURKANOTUM | |
| SCHEMBL4484875 | 0.76 | CCNA2 (0.37) | CCNA2CDK2CCNA1AURKANOTUM | |
| SCHEMBL2915617 | 0.76 | AURKA (0.44) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL2921266 | 0.75 | CCNA2 (0.63) | CCNA2CDK2CCNA1AURKANOTUM | |
| SCHEMBL5720814 | 0.75 | KCNK3 (0.39) | CCNA2CDK2CCNA1AURKANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-06-22 | — | — | US | disclosed |
| EP-1527074-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004013144-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA SPA (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K5, MAP3K19 | CCNA2 915/4885CDK2 52/4885CCNA1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.